Mass Tort brief
Mass Tort & Consumer Class Actions: Israeli Food Labels, Teva Bellwethers, and Telecom Settlements
Israeli courts advance key consumer class actions while domestic giants Teva and Alarum navigate high-stakes litigation in US federal court.
Mass Tort
Teva faces imminent U.S. bellwether trials that could force settlement negotiations across thousands of pending medical device breakage claims.
BackgroundProduct liability multidistrict litigation allows federal courts to consolidate similar injury claims for pre-trial discovery and test trials. Teva Pharmaceutical Industries is headquartered in Israel, with commercial operations managing global device distribution.
- Plaintiffs claim the device's flexible arms break during removal procedures, causing internal tissue damage and requiring surgical extraction.
- Judge Leigh Martin May scheduled the next bellwether trial, Robere v. Teva, to begin September 28 in Georgia federal court.
- Discovery proceedings experienced delays due to regional operational adjustments at Teva's corporate headquarters in Israel, extending overall litigation timelines.
Mass Tort
The court's approval of a ₪350 million class action establishes strict liability for misleading nutritional claims across Israel's retail food industry.
BackgroundIsraeli consumer protection regulations impose strict labeling standards for food items designated as sugar-free. Retail food chains face substantial statutory liability if product nutritional labels mislead health-conscious or diabetic consumers.
- Independent laboratory testing revealed hazelnut and coffee flavors contained 6.6 grams of sugar per 100g compared to the 0.5g statutory cap, triggering widespread consumer fraud claims.
- Judge Iris Rabinovitch-Brun rejected defense arguments that 'sugar-free' referred only to added sucrose ingredients, establishing that total sugar content dictates statutory compliance.
- The certified class represents consumers who purchased affected dietary flavors across Golda's 100+ national branches over seven years, establishing significant potential statutory damages.
Mass Tort
Teva is acting to prevent geopolitical sentiment from influencing American jurors in multi-billion-dollar price-fixing litigation.
BackgroundTeva is defending against antitrust allegations claiming major generic drug manufacturers conspired to inflate prices. Defense attorneys frequently file motions in limine to exclude potentially prejudicial, non-material background information from jury trials.
- Teva argued national origin is legally irrelevant to determining liability in commercial price-fixing allegations, citing risk of unfair jury prejudice.
- Plaintiff Humana opposes the motion, seeking full corporate disclosure regarding Teva's global operational structure and executive decision-making locations.
- The federal trial addressing industry-wide generic price-fixing claims is scheduled to open on September 15 in Pennsylvania federal court.
Mass Tort
Parallel securities lawsuits threaten Alarum's balance sheet after law enforcement scrutiny into its core routing network shattered investor confidence.
BackgroundAlarum Technologies is listed on NASDAQ and develops internet privacy and data collection tools. NetNut provides residential proxy infrastructure that routes web traffic through consumer network addresses.
- Plaintiffs allege NetNut co-opted consumer home internet devices without consent to route cybercrime traffic, exposing the parent company to massive legal exposure.
- Alarum's American Depositary Shares dropped over 50% following media reports detailing the law enforcement probe, wiping out substantial market valuation.
- The class action suit Cygler v. Alarum Technologies was filed in the U.S. District Court for New Jersey, targeting board oversight failure.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
